Table 1.
Clinical characteristics of patients with unresectable HCC.
| Variables | Whole cohort (n=91) |
|---|---|
| Sex (Female/Male) | 16 (17.6%)/75 (82.4%) |
| Age, year, median (Q1, Q3) | 53.0 (46.0, 58.0) |
| Liver cirrhosis (No/Yes) | 39 (42.9%)/52 (57.1%) |
| Child-Pugh (A/B) | 88 (96.7%)/3 (3.3%) |
| ALBI, median (Q1, Q3) | -2.78 (-2.94, -2.55) |
| ALBI grade | |
| 1 | 64 (70.3%) |
| 2 | 27 (29.7%) |
| 3 | 0 (0%) |
| HBsAg (Negative/Positive) | 13 (14.3%)/78 (85.7%) |
| HBV-DNA load, IU/ml (≤2000/>2000) | 60 (65.9%)/31 (34.1%) |
| Antivirus therapy (No/Yes) | 49 (53.8%)/42 (46.2%) |
| AFP, μg/L (≤20/>20) | 27 (29.7%)/64 (70.3%) |
| PIVKA-II, μg/L (≤37/>37) | 15 (16.5%)/76 (83.5%) |
| CEA, μg/L (≤10/>10) | 87 (95.6%)/4 (4.4%) |
| CA19-9, μg/L (≤39/>39) | 71 (78.0%)/20 (22.0%) |
| Maximum tumor size, cm, median (Q1, Q3) | 6.0 (4.0, 9.0) |
| Tumor number (1/2/3/≥4) | 33 (36.3%)/27 (29.7%)/10 (11.0%)/21 (23.1%) |
| Lymph node metastasis (No/Yes) | 81 (89.0%)/10 (11.0%) |
| Extrahepatic metastasis (No/Yes) | 70 (76.9%)/21 (23.1%) |
| Macrovascular invasion | |
| No | 62 (68.1%) |
| Portal vein | 9 (9.9%) |
| Hepatic vein | 16 (17.6) |
| Portal vein combined with hepatic vein | 4 (4.4%) |
| Duration time, month, median (Q1, Q3) | 8.0 (4.0, 12.0) |
| BCLC (A/B/C) | 9 (9.9%)/30 (33.0%)/52 (57.1%) |
| CNLC stage (Ia-Ib/IIa-IIb/IIIa-IIIb) | 13 (14.3%)/27 (29.7%)/51 (56.0%) |
HCC, hepatocellular carcinoma; ALBI, Albumin-bilirubin grade; Q1, first quartile; Q3, third quartile; AFP, alpha-fetoprotein; PIVKA-II, Protein Induced by Vitamin K Absence or Antagonist-II; CA19-9, carbohydrate antigen 19-9; CEA, carcino-embryonic antigen; HBsAg, hepatitis B surface antigen; HBV-DNA, hepatitis B virus deoxyribonucleic acid; BCLC, Barcelona Clinic Liver Cancer; CNLC, China liver cancer staging.